International Journal of Engineering Research & Management Technology
(Peer-Reviewed, Open Access, Fully Refereed International Journal) ISSN: 2348-4039
Volume 11, Issue-5, September-October- 2024 Impact Factor: 7.09
Email: editor@ijermt.org www.ijermt.org

"ANALYZING EFFECT OF GOVERNMENT POLICIES ON GROWTH AND DEVELOPMENT OF INDIAN PHARMACEUTICAL INDUSTRY"

1. **Dr. Tarun Jain, Assistant Professor, Department of Commerce, D. J. College Baraut.**
2. **Nikhil, Research Scholar, Department of Commerce, D. J. College Baraut.**

ABSTRACT

The Indian pharmaceutical industry is one of the largest in the world, playing a critical role in global healthcare, especially by supplying affordable generic medicines. This paper analyzes the influence of government policies on the Indian pharmaceutical sector, evaluating the regulatory framework, incentives, and policies such as Drug Price Control Orders (DPCO), National Pharmaceutical Pricing Authority (NPPA), the Make in India initiative, and the Production Linked Incentive (PLI) scheme. The study examines how these policies affect innovation, competitiveness, pricing, access to medicine, and the global positioning of the industry.

Keywords: *Indian Pharmaceutical Industry, Government Policies, Drug Pricing, Make In India, Pli Scheme, Innovation, Regulations, Healthcare.*

1.1 INTRODUCTION

The Indian pharmaceutical industry is one of the largest and most significant sectors in the country, contributing to its economy and healthcare system. The industry is renowned globally for its role in the production of affordable generic drugs, making vital medicines accessible to people around the world. India, often referred to as the "pharmacy of the world," is responsible for supplying approximately 50% of the global demand for vaccines, 40% of the generic medicines in the U.S., and 25% of all medicines in the U.K. With a market size exceeding $50 billion, it is the third-largest pharmaceutical market by volume globally, and it is projected to reach over $130 billion by 2030.The growth and success of the Indian pharmaceutical industry have been deeply influenced by various government policies, frameworks, and regulatory measures. These policies have been aimed at fostering innovation, ensuring affordability, and promoting both domestic manufacturing and exports. Over the years, India has implemented several initiatives to strengthen the pharmaceutical sector, regulate pricing, encourage investments, and streamline manufacturing processes. However, government intervention has been a double-edged sword, offering both opportunities and challenges for the industry. While policies like the Drug Price Control Orders (DPCO), the National Pharmaceutical Pricing Authority (NPPA), and the introduction of initiatives such as Make in India and the Production Linked Incentive (PLI) scheme have boosted the growth of the sector, they have also posed challenges related to regulation, profitability, innovation, and competition.

India's pharmaceutical landscape has witnessed various shifts in policy due to changing healthcare needs, political landscapes, and global dynamics. One of the most crucial and often discussed policies is the DPCO, which is intended to regulate the prices of essential medicines and ensure that they remain affordable

for all sections of society. While this policy aims to make healthcare more accessible, it has also led to debates over its impact on the profitability of pharmaceutical companies and their ability to reinvest in research and development (R&D). The role of the NPPA in implementing price controls and monitoring the availability of essential drugs further amplifies the tension between affordable healthcare and industry profitability.In recent years, government policies have increasingly focused on encouraging domestic manufacturing, reducing dependence on imports, and positioning India as a global leader in pharmaceutical exports. The Make in India initiative, launched in 2014, has sought to promote domestic production in various sectors, including pharmaceuticals, through incentives and regulatory reforms. By reducing reliance on imports, particularly Active Pharmaceutical Ingredients (APIs), India aimed to secure its pharmaceutical supply chain, especially after disruptions in global trade. The scheme also attracted foreign direct investment (FDI), which played a pivotal role in modernizing the manufacturing infrastructure and promoting innovation within the sector.

The introduction of the Production Linked Incentive (PLI) scheme in 2020 further supported India's goal of becoming self-reliant in pharmaceutical manufacturing. The PLI scheme incentivizes companies to increase production in specific areas, such as APIs and key pharmaceutical products, to meet both domestic and international demand. This initiative aims to reduce India's dependence on China for critical raw materials, especially in the wake of global supply chain disruptions caused by the COVID-19 pandemic. While these policies have been instrumental in driving growth and increasing the global competitiveness of Indian pharmaceutical companies, they have also highlighted several issues related to implementation, regulatory hurdles, and uneven distribution of benefits across the industry.Intellectual property rights (IPR) and patent laws are also key areas where government policies have significantly impacted the pharmaceutical industry. India's decision to amend its patent laws in 2005, in compliance with the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, has shaped the competitive landscape of the pharmaceutical sector. While the reform facilitated the introduction of product patents, which are critical for fostering innovation, it also introduced challenges for the generics industry. The new patent regime meant that Indian pharmaceutical companies could no longer produce generic versions of patented medicines, leading to concerns about rising drug prices for essential therapies. At the same time, India's approach to balancing patent protection with public health needs has allowed for the production of affordable generic medicines, ensuring that low-cost alternatives are available to patients worldwide.

1.2 GOVERNMENT POLICIES AND THEIR IMPACT ON THE INDIAN PHARMACEUTICAL INDUSTRY

The Indian pharmaceutical industry is one of the largest in the world, both in terms of volume and value, and has played a crucial role in global healthcare. This success has largely been shaped by government policies, which have regulated, nurtured, and at times challenged the industry. These policies have ranged from price controls to incentivizing research and development (R&D), export promotion, intellectual property rights (IPR) reform, and regulatory oversight. Over the decades, the government's approach has evolved in response to shifting domestic and global healthcare needs, market dynamics, and the industry's increasing role in global medicine supply.

The government has historically used policies to strike a balance between encouraging the growth of the pharmaceutical industry and ensuring that the population has access to affordable medicines. While these policies have fueled the sector's growth, they have also posed challenges in terms of profitability,

innovation, and market competition. This article examines key government policies that have influenced the Indian pharmaceutical industry and analyzes their impact.

1.2.1 Drug Price Control and Regulation

One of the most significant policy interventions in the Indian pharmaceutical industry has been the regulation of drug prices. The government has implemented various measures to control the prices of essential medicines, with the aim of making healthcare affordable to all segments of the population. The primary mechanism for regulating drug prices in India has been the Drug Price Control Order (DPCO), which has been revised several times since its introduction in 1979. Under DPCO, the government sets price ceilings for essential medicines, ensuring that pharmaceutical companies cannot charge excessive prices for life-saving drugs.

The DPCO has been a double-edged sword for the pharmaceutical industry. On the one hand, it has allowed millions of Indians to access affordable medicines, especially for diseases like tuberculosis, diabetes, and hypertension. On the other hand, it has constrained the profitability of pharmaceutical companies, particularly in the generics market. While large players have generally managed to absorb the impact of price controls, smaller companies face significant challenges in maintaining margins and reinvesting in research and development. Price controls have also raised concerns about the long-term sustainability of the industry's innovation and competitiveness. The government's introduction of National List of Essential Medicines (NLEM), which identifies critical drugs that must be kept at affordable prices, has further amplified these debates.

1.2.2 Intellectual Property and Patent Laws

The evolution of intellectual property (IP) and patent laws in India has played a pivotal role in shaping the pharmaceutical industry. Prior to 2005, India had a patent law that did not allow product patents on pharmaceuticals. This system enabled Indian pharmaceutical companies to reverse-engineer and produce generic versions of patented drugs, significantly reducing the cost of medicines. This practice not only made healthcare more affordable in India but also turned India into the "pharmacy of the world," supplying affordable generic medicines globally.

However, with the advent of the TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights) under the World Trade Organization (WTO), India was required to amend its patent laws to grant product patents on pharmaceutical products. The Patent (Amendment) Act of 2005 was introduced to comply with TRIPS, allowing product patents for new inventions. This reform was seen as a significant change for the Indian pharmaceutical industry, as it meant that generic drug manufacturers could no longer produce copies of patented medicines. This policy shift created concerns about rising drug prices and the potential impact on the affordability of essential medicines in India and other developing countries.

However, India's patent laws have also incorporated mechanisms to balance the interests of public health and innovation. The Compulsory Licensing provision, which allows the government to grant licenses for the production of patented drugs under certain conditions (e.g., public health emergencies), has been an essential tool in ensuring continued access to affordable medicines. A landmark case in 2012, where India's Patent Office granted a compulsory license for the production of a generic version of the cancer drug

Nexavar (sorafenib), exemplified how India's patent laws can be used to ensure that patents do not inhibit access to life-saving medicines.

The pharmaceutical industry has had to adapt to these changes, with a greater focus on the development of novel drugs, formulations, and biologics to retain a competitive edge. While the new patent regime has encouraged innovation, it has also led to more legal battles, particularly in cases involving incremental innovation and patent evergreening (a practice where companies make slight modifications to existing drugs to extend their patent life).

1.2.3. Export Promotion and Global Competitiveness

India's pharmaceutical industry has become a global leader in the production and export of generics, thanks to the government's focus on export promotion policies. India's pharmaceutical exports have seen remarkable growth, driven by low-cost manufacturing capabilities, a large pool of skilled labor, and a favorable regulatory environment. The government has supported this growth through incentives such as the Foreign Trade Policy (FTP), which provides tax benefits and subsidies to companies that export pharmaceutical products.

In 2004, the Pharmaceutical Export Promotion Council of India (Pharmexcil) was established to promote Indian pharmaceutical exports and represent the interests of the industry. Through various initiatives, including participation in international trade fairs and addressing regulatory challenges, Pharmexcil has played a significant role in expanding India's footprint in the global pharmaceutical market.

Moreover, India's compliance with international Good Manufacturing Practices (GMP) standards and its accreditation from global regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have further boosted the reputation of Indian pharmaceutical products. Indian companies such as Sun Pharma, Cipla, Dr. Reddy's, and Lupin have become household names globally, particularly in the U.S., where Indian generics hold a significant share of the market.

The Indian government's strategic policies to enhance export competitiveness, including providing incentives for the manufacture of high-value, high-complexity products like biosimilars and biopharmaceuticals, have also been important in positioning India as a leader in the global pharmaceutical market.

1.2.4. Production Linked Incentive (PLI) Scheme

In recent years, India has introduced the Production Linked Incentive (PLI) Scheme to boost domestic manufacturing in key sectors, including pharmaceuticals. The scheme, which was launched in 2020, aims to reduce India's dependence on imports, particularly from China, for critical Active Pharmaceutical Ingredients (APIs). Under the PLI scheme, the government offers incentives to companies for manufacturing certain pharmaceutical products domestically, thereby encouraging the establishment of new production facilities and the expansion of existing ones.

The PLI scheme is expected to drive growth in the API sector and improve India's self-reliance in pharmaceutical manufacturing. By promoting the production of APIs and reducing reliance on imports, India can strengthen its pharmaceutical supply chain, safeguard against supply disruptions, and improve the

overall competitiveness of its pharmaceutical companies. This initiative is also expected to attract foreign direct investment (FDI) and create jobs in the pharmaceutical manufacturing sector.

1.1.5. Regulatory Reforms and the National Medical Device Policy

The Indian pharmaceutical industry is regulated by a complex framework, which includes the Drugs and Cosmetics Act, the Central Drugs Standard Control Organization (CDSCO), and state-level regulators. These regulations are designed to ensure the safety, efficacy, and quality of medicines in India. The Indian government has implemented several reforms to streamline regulatory processes and reduce the time required for drug approvals. For example, in 2014, the New Drugs and Clinical Trials Rules were introduced to improve the approval process for new drugs and clinical trials, ensuring that they are more efficient and transparent.

Additionally, the Indian government has increasingly recognized the importance of the medical devices sector, which is integral to the pharmaceutical industry. The National Medical Device Policy 2020 aims to strengthen the domestic manufacturing of medical devices, ensure quality standards, and foster innovation in the sector. This policy is expected to complement the pharmaceutical industry's growth by encouraging the development of a robust medical devices ecosystem in India.

Government policies have played an instrumental role in shaping the growth and development of the Indian pharmaceutical industry. Price control measures, patent law reforms, export promotion, and the recent PLI scheme have driven the industry's success both domestically and globally. These policies have allowed India to become a leader in the production and export of affordable generic medicines, making significant contributions to global healthcare. However, challenges remain, particularly with regard to balancing affordability with innovation, dealing with regulatory hurdles, and ensuring sustainable growth in an increasingly competitive global market.

The future of the Indian pharmaceutical industry will largely depend on the government's ability to continuously adapt policies that foster innovation, reduce reliance on imports, and ensure the affordability of medicines for all citizens. With the right mix of regulatory oversight and policy support, the Indian pharmaceutical industry is well-positioned to maintain its leadership role in global healthcare and contribute to improved health outcomes worldwide.

1.3 CHALLENGES FACED BY THE INDIAN PHARMACEUTICAL INDUSTRY DUE TO GOVERNMENT POLICIES

The Indian pharmaceutical industry has grown to become one of the largest in the world, contributing significantly to both domestic healthcare and the global supply of affordable medicines, especially generics. However, the Indian pharmaceutical industry, despite its success, faces a series of challenges due to the government policies that regulate it. While these policies have helped in making medicines affordable, enhancing export competitiveness, and supporting domestic manufacturing, they have also posed challenges related to innovation, pricing, regulatory compliance, and competition. The government's regulatory framework, although designed to foster growth and access to medicines, can sometimes create an environment of uncertainty and operational difficulty for pharmaceutical companies. This paper outlines the

various challenges faced by the Indian pharmaceutical industry as a result of the government's policies and interventions.

1.3.1 Price Control and Its Impact on Profitability

The Indian government's Drug Price Control Orders (DPCO), which regulate the prices of essential medicines, have been a crucial policy for ensuring that medicines are affordable for the general public. Under the DPCO, the government fixes the prices of medicines deemed essential, including critical life-saving drugs like antibiotics, cancer medications, and cardiovascular drugs. The pricing of these medicines is based on an average of prices of branded medicines in the market, as well as the prices of medicines produced by major companies. This price control mechanism is intended to provide affordable medicines to all sections of society.

However, the price control policies have posed several challenges for pharmaceutical companies, particularly those involved in the production of generics. Although these companies are able to produce drugs at lower costs compared to branded alternatives, price controls limit their ability to achieve significant profit margins, especially for the medicines included in the essential list. Smaller pharmaceutical companies often struggle with these controls as the prices set by the government may not cover the full cost of production, thereby leading to lower margins and reduced incentives to invest in new product development or improve quality.

In some cases, price controls can also discourage foreign direct investment (FDI) in the Indian pharmaceutical market, as potential investors may perceive the regulatory environment as restrictive. Larger companies with diversified portfolios may absorb the impact of price controls, but smaller players face the challenge of maintaining profitability while adhering to the regulations.

1.3.2. Impact of Intellectual Property Rights (IPR) Reforms on Innovation

In 2005, India amended its Patent Act to comply with the TRIPS (Trade-Related Aspects of Intellectual Property Rights) agreement under the World Trade Organization (WTO), which granted product patents for pharmaceutical inventions. Prior to the amendment, India's pharmaceutical industry enjoyed a robust generics market because Indian firms could reverse-engineer and manufacture generic versions of patented drugs without violating intellectual property rights. This contributed significantly to the growth of the industry, allowing it to offer affordable alternatives to costly branded medicines.

However, with the implementation of product patents, the situation has changed. Indian pharmaceutical companies now face restrictions on the production of generic versions of patented drugs, leading to concerns over rising drug prices. The patent law reform is perceived as favoring multinational pharmaceutical companies, which hold the patents on many high-cost drugs. This not only increases the cost of medications for Indian consumers but also limits the capacity of Indian companies to produce affordable generics. While the law allows for compulsory licensing in cases of public health emergencies, it is not a universal solution and has not always been applied in practice.

Furthermore, the need for compliance with international intellectual property laws has increased litigation risks. Multinational pharmaceutical companies often sue Indian generic manufacturers for patent infringement, resulting in protracted legal battles. While India's patent laws include provisions to prevent

evergreening (a practice where companies make slight modifications to a drug to extend its patent), the introduction of more complex patent litigation frameworks has led to increased costs for Indian pharmaceutical companies and created an uncertain business environment.

1.3.3 Regulatory and Compliance Issues

The Indian pharmaceutical industry is governed by a complex regulatory framework, including the Drugs and Cosmetics Act, administered by the Central Drugs Standard Control Organization (CDSCO). The regulations cover the approval and manufacturing of drugs, clinical trials, and post-market surveillance. While these regulations are designed to ensure the safety and efficacy of medicines, compliance with them can be a significant burden for pharmaceutical companies, especially small and medium-sized enterprises (SMEs).

The approval process for new drugs and clinical trials can be slow, which delays the entry of new medicines into the market. This delay is particularly problematic for companies attempting to introduce novel drugs and formulations. Moreover, the Regulatory Authority sometimes faces resource constraints, leading to longer timelines for inspections, approvals, and product registrations. Pharmaceutical companies must also comply with international regulatory standards to sell drugs in global markets, which requires additional investments in quality control, certifications, and adherence to Good Manufacturing Practices (GMP).

The compliance burden is particularly challenging for smaller pharmaceutical firms, which may lack the resources to navigate the complex regulatory processes. Regulatory uncertainties and delays in approvals may lead to missed market opportunities and hinder the ability to launch new products in a timely manner.

1.3.4. Increased Competition from Multinational Companies

India's pharmaceutical industry has long been dominated by generics, and the government's pro-generics policies have played an important role in its global success. However, with the adoption of TRIPS and the introduction of product patents, multinational pharmaceutical companies have gained a stronger foothold in the Indian market. These companies now have exclusive patent rights to many high-value drugs, which has escalated competition for domestic generics manufacturers.

Multinational companies often have significantly larger financial resources, advanced R&D capabilities, and better access to global markets. As a result, Indian pharmaceutical companies face intense competition, particularly in the high-value therapeutic areas, such as biologics, oncology, and specialty drugs. While Indian companies still dominate in the generics market, the rise of multinational players has led to pricing pressures and a need for Indian firms to invest in developing novel drugs, differentiated products, and niche segments.

Moreover, these multinational corporations have strong marketing and distribution networks, enabling them to maintain a competitive advantage in the marketplace. For Indian pharmaceutical companies to maintain their market share, they must either compete on pricing (which is constrained by government price controls) or focus on innovation and the development of high-value, complex medicines.

1.3.5. Dependence on Imported Active Pharmaceutical Ingredients (APIs)

The Indian pharmaceutical industry's reliance on imported Active Pharmaceutical Ingredients (APIs), particularly from China, has been a longstanding challenge. Despite India being one of the world's largest producers of pharmaceuticals, a significant portion of its raw material requirements—especially for key APIs—comes from external suppliers. This reliance on imports leaves the Indian pharmaceutical sector vulnerable to disruptions in the supply chain, especially in cases of geopolitical tensions or disruptions like the COVID-19 pandemic, which exposed the fragility of global supply chains.The Indian government has recognized this vulnerability and introduced the Production Linked Incentive (PLI) Scheme to encourage the domestic production of critical APIs. While the scheme aims to reduce India's dependence on China and other countries for essential raw materials, the transition to domestic API manufacturing will take time, and companies may face challenges in terms of investment, infrastructure, and scaling up production.

1.3.6. Bureaucratic and Administrative Delays

The Indian pharmaceutical industry is often hampered by bureaucratic inefficiencies and administrative delays. The approval processes for new drugs, clinical trials, and regulatory certifications can be cumbersome and time-consuming. While the government has taken steps to streamline regulatory processes, the existing systems still pose significant hurdles. For instance, delays in drug approvals and testing results in missed market opportunities and stymies the launch of new medicines. Additionally, companies may face challenges in meeting the necessary compliance requirements for international markets, particularly when navigating regulations imposed by different countries.

The government policies implemented to regulate the Indian pharmaceutical industry have both positive and negative consequences. On one hand, measures like drug price controls, IPR reforms, and export promotion initiatives have spurred growth, affordability, and global competitiveness. On the other hand, policies such as stringent price controls, regulatory complexities, and patent law reforms have posed significant challenges to the industry's profitability, innovation, and operational efficiency. The future success of the Indian pharmaceutical industry depends on the ability of the government to strike a delicate balance between encouraging growth, fostering innovation, and ensuring affordable access to medicines for the population. Addressing the challenges posed by these policies will require a collaborative approach, where the government works closely with industry stakeholders to foster a more dynamic, resilient, and competitive pharmaceutical sector.

1.4 CONCLUSION

While government policies have played a crucial role in shaping the growth of the Indian pharmaceutical industry, they have also presented several challenges. Price controls, intellectual property reforms, and regulatory complexities have constrained profitability, slowed innovation, and increased competition. Additionally, the reliance on imported APIs and bureaucratic delays have further complicated the industry's operations. However, policies such as the PLI Scheme and export promotion efforts hold potential for mitigating some of these challenges. Moving forward, a balanced approach that encourages innovation, supports domestic manufacturing, and ensures affordable healthcare will be vital for sustaining the growth and global leadership of the Indian pharmaceutical sector.

REFERENCES

- Ayati, N., Saiyarsarai, P., &Nikfar, S. (2020). Short and long-term impacts of COVID-19 on the pharmaceutical sector. *DARU Journal of Pharmaceutical Sciences*, 28, 1-7. https://doi.org/10.1007/s40199-020-00358-5
- Ayati, N., Saiyarsarai, P., &Nikfar, S. (2020). Short and long-term impacts of COVID-19 on the pharmaceutical sector. *DARU Journal of Pharmaceutical Sciences*, 28(2), 799-805.
- Bulgakov, A. L., &Kosmakov, R. V. (2018). Pharmaceutical partnerships in the development of new pharmaceuticals. *Pharmacy & Pharmacology*, 6(1), 86-98.
- Devi, Dr., & Scholar. (2020). A study on future and prospects of the Indian pharmaceutical industry post-COVID. *History Research Journal, UGC CARE Journal*, 30(1), 9-12.
- Joshi, H. (2023). Analysis of the Indian pharmaceutical industry: With emphasis on opportunities in 2005. *Pharmaceutical Technology*, *2003*(1), 74-94.
- Kamat, S. R., & Dutta, P. (2018). India's drug price control policy: A historical perspective. *Journal of Health Policy and Management, 7*(2), 1-14.
- Langer, E., & Kelkar, A. (2008). Pharmaceutical distribution in India. *BioPharm International*, 2-5.
- Zhou, Y., Mi, J., Yu, N., & Wang, C. (2012). Analysis of government policies in the pharmaceutical industry. *Information Technology Journal*, *11*(9), 1272-1278. https://doi.org/10.3923/itj.2012.1272.1278.
- Jadhav, N., Singh, N., Targhotra, M., & Chauhan, M. (2020). Impact of COVID-19 on Indian pharmaceutical industry and way forward. *Infectious Disorders - Drug Targets*, 20(4), 1-10.
- Nezhnikova, E. V., &Maksimchuk, M. V. (2019). Pharmaceutical industry in the Russian Federation: Problems and development prospects. *RUDN Journal of Economics*, 27(1), 102-112.
- Suleymankadieva, A. E., Petrov, M. A., Mitina, A. S., &Tumarov, T. F. (n.d.). Modern trends of integration processes in the pharmaceutical industry: Particularities and prospects of strategic partnerships and alliances. *Journal of Economics, Entrepreneurship and Law*, 10(4), 1-10.
- Velinov, E. E., Zobov, A., &Fedorenko, E. (2021). Impact of COVID-19 on the formation of strategic alliances of pharmaceutical companies in the context of sustainable development (on the example of EU and Russian markets). *International Journal of Entrepreneurship*, 25(5), 1-10.
- Gopakumar, G., &Sathyanarayana, R. (2020). Impact of government policies on the Indian pharmaceutical industry: A review. *Indian Journal of Pharmaceutical Sciences, 82*(3), 425-430.